Rapyd Launches Stablecoin Payment Solutions: Digital Versatility Meets Dollar Stability
9.9.2025 14:00:00 CEST | Business Wire | Press Release
Rapyd, a leading global fintech company, today announced the launch of its Stablecoin Payment Solutions, giving businesses a secure and scalable way to accept stablecoins, settle in stablecoins and pay out using stablecoins.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250909572698/en/
Rapyd makes stablecoin payments seamless: Accept, settle, and pay out in one platform
2025 is the year stablecoins are moving from early-stage concept to real-world utility. Total volumes across blockchains surpassed $27 trillion1, surpassing the combined payment volumes of Visa and Mastercard in the same year2. That scale is beginning to reshape industries from gaming, to e-commerce, to traditional retail. Now, Rapyd is making it usable for enterprises in everyday payments and settlements.
Rapyd’s new suite of products addresses a central need for companies navigating volatile currencies, slow settlement times, and complex treasury operations. With Rapyd as a single provider, businesses can accept, settle, or send payouts instantly, eliminating the need for fragmented systems or multiple intermediaries. Businesses can now use Rapyd to:
- Accept Stablecoin Payments from global customers and instantly convert into preferred fiat currencies.
- Send Stablecoin Payouts securely to businesses and end users anywhere in the world, 24/7/365.
- Settle in Stablecoins to improve liquidity and reduce reliance on traditional rails like SWIFT or ACH.
“Stablecoins have moved from early-stage concept to global utility, and companies need partners who can bridge digital assets with real-world business needs,” said Arik Shtilman, CEO and Co-Founder of Rapyd. “Rapyd’s role is to strip away the complexity, integrate stablecoins into global money movement, and give businesses more control over how and when they move funds.”
The launch comes at a pivotal moment. New regulations in the US (GENIUS Act) and Europe (MiCA), along with similar initiatives in other major markets, are accelerating adoption by legitimizing stablecoins and setting clear operating standards. This regulatory clarity, combined with demand from industries such as gaming and online trading, is creating the most significant shift in financial infrastructure since the rise of card networks.
“Enterprises are under pressure to manage liquidity in real time while navigating multiple currencies and jurisdictions,” said David Rosa, General Manager of Rapyd’s Scale Business Unit. “Our Stablecoin Payment Solutions are built to remove those barriers. By combining stablecoin rails with our existing treasury, payout, and settlement infrastructure, we give CFOs and operations teams the ability to move funds instantly, reduce FX exposure, and cut out unnecessary intermediaries. It’s about taking what has been a fragmented, complex process and turning it into a single, reliable platform for global money movement.”
Rapyd’s end-to-end solution is designed for enterprises that need stability and speed in cross-border payments. For businesses operating globally, this means faster payouts. For platforms and marketplaces, it could reduce FX exposure. For the creator economy, it enables beneficiaries to receive payments with an instrument that is pegged to a currency value, even in emerging markets. By combining stablecoin rails with Rapyd’s existing global payments network, the company is positioning itself as the single provider for businesses seeking flexibility in both fiat and digital currencies.
For more information, visit: rapyd.net/solutions/stablecoin-payments
About Rapyd
Rapyd lets you build bold. Liberate global commerce with all the tools your business needs to create payment, payout and fintech experiences everywhere. From Fortune 500s to ambitious business and technology upstarts, our payments network and powerful fintech platform make it easy to pay suppliers and get paid by customers—locally or internationally.
With offices worldwide, including London, Tel Aviv, Dubai, Iceland, Amsterdam, San Francisco, Miami, Hong Kong and Singapore, we know what it takes to make cross-border commerce as easy as being next door. Rapyd simplifies payments so you can focus on building your business.
Get the tools to grow globally and learn about our products, solutions and partner programmes at www.rapyd.net. Follow: Blog, Insta, LinkedIn, Twitter.
1 Coin Telegraphcointelegraph.com/news/stablecoins-beat-visa-mastercard-2024-volume
2 CCN
Disclaimer
Rapyd’s stablecoin-related services are enabled through partnerships with regulated third-party providers. Rapyd does not itself issue, custody, or directly process crypto assets. All crypto-related services are subject to the terms, conditions, and regulatory status of Rapyd’s third-party partners. These services are delivered in collaboration with trusted third-party providers, ensuring compliance and security across all stablecoin transactions. Rapyd works with partners that adhere to applicable regulatory requirements in each jurisdiction. This Press Release is not an invitation or inducement to engage in investment activity, and does not seek to promote any such services or similar activities.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250909572698/en/
Contacts
Media Contact: press@rapyd.net
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press Release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press Release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press Release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press Release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press Release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom